# Characterization of Age and Polarity at Onset in Bipolar Disorder

Janos L. Kalman<sup>1,2,3</sup>, MD,\* Loes M. Olde Loohuis<sup>4</sup>, PhD,\* Annabel Vreeker<sup>5</sup>, PhD,\* Andrew McQuillin<sup>6</sup>, PhD, Eli A. Stahl<sup>7</sup>, PhD, Douglas Ruderfer<sup>8,9,10</sup>, PhD, Maria Grigoroiu-Serbanescu<sup>11</sup>, PhD, Georgia Panagiotaropoulou<sup>12</sup>, M.Sc., Stephan Ripke<sup>13,14</sup>, M.D., Ph.D., Tim B Bigdeli<sup>15,16</sup>, PhD, Frederike Stein<sup>17</sup>, M.A., Tina Meller<sup>17,18</sup>, Dr. rer. nat., M.Sc., Susanne Meinert<sup>19</sup>, M.Sc., Helena Pelin<sup>3,20</sup>, M.Sc., Fabian Streit<sup>21</sup>, PhD, Sergi Papiol<sup>1,2,22</sup>, PhD, Mark J Adams<sup>23</sup>, PhD, Rolf Adolfsson<sup>24</sup>, MD, PhD, Kristina Adorjan<sup>1,2</sup>, MD, Ingrid Agartz<sup>25,26,27</sup>, MD, PhD, Sofie R. Aminoff<sup>28,29</sup>, PhD, Heike Anderson-Schmidt<sup>30</sup>, Dipl-Psych, Ole A. Andreassen<sup>29,31</sup>, MD, PhD, Raffaella Ardau<sup>32</sup>, Jean-Michel Aubry<sup>33,34</sup>, MD, Ceylan Balaban<sup>35</sup>, M.Sc., Nicholas Bass<sup>6</sup>, MRCPsych, Bernhard T Baune<sup>19</sup>, MD, PhD, Frank Bellivier<sup>36,37,38</sup>, MD, PhD, Antonio Benabarre<sup>39</sup>, MD, PhD, Susanne Bengesser<sup>40</sup>, MD, PhD, Wade H Berrettini<sup>41</sup>, MD, PhD, Marco P. Boks<sup>42</sup>, MD, PhD, Evelyn J Bromet<sup>43</sup>, PhD, Katharina Brosch<sup>17</sup>, M.Sc., Monika Budde<sup>1</sup>, Dipl-Psych, William Byerley<sup>44</sup>, MD, Pablo Cervantes<sup>45</sup>, MD, Catina Chillotti<sup>32</sup>, Sven Cichon<sup>46,47,48,49</sup>, Prof. Dr. rer.nat., Scott R Clark<sup>50,51</sup>, MD, PhD, Ashley L. Comes<sup>1,3</sup>, PhD, Aiden Corvin<sup>52</sup>, MD, PhD, William Coryell<sup>53</sup>, MD, Nick Craddock<sup>54</sup>, MD, David W. Craig<sup>55</sup>, PhD, Paul E. Croarkin<sup>56</sup>, D.O., M.S., Cristiana Cruceanu<sup>3</sup>, PhD, Piotr M. Czerski<sup>57</sup>, PhD, Nina Dalkner<sup>40</sup>, PhD, Udo Dannlowski<sup>19</sup>, MD, PhD, Franziska Degenhardt<sup>47,58</sup>, MD, J. Raymond DePaulo<sup>59</sup>, MD, Srdjan Djurovic<sup>60,61</sup>, PhD, Howard J. Edenberg<sup>62</sup>, PhD, Mariam Al Eissa<sup>6</sup>, PhD, Torbjørn Elvsåshagen<sup>63</sup>, MD, PhD, Bruno Etain<sup>36,37,38</sup>, MD, PhD, Ayman H Fanous<sup>15,16</sup>, MD, Frederike Fellendorf<sup>40</sup>, MD, Alessia Fiorentino<sup>6</sup>, PhD, Andreas J Forstner<sup>47,64</sup>, MD, Mark A. Frye<sup>56</sup>, MD, Janice M. Fullerton<sup>65,66</sup>, PhD, Katrin Gade<sup>67</sup>, MD, Julie Garnham<sup>68</sup>, BN RN, Kirov George<sup>54</sup>, PhD, MD, Elliot Gershon<sup>69,70</sup>, MD, Michael Gill<sup>52</sup>, MD, Fernando S. Goes<sup>59</sup>, MD, Katherine Gordon-Smith<sup>71</sup>, PhD, Paul Grof<sup>72,73</sup>, MD, PhD, Jose Guzman-Parra<sup>74</sup>, PhD, Tim Hahn<sup>19</sup>, PhD, Maria Hake<sup>1</sup>, Dipl.-Psych., Roland Hasler<sup>33,34</sup>, PhD, Urs Heilbronner<sup>1</sup>, PhD, Stephane Jamain<sup>75,76</sup>, PhD, Esther Jimenez<sup>39</sup>, MSc, PhD, Ian Jones<sup>54</sup>, PhD, MD, Lisa Jones<sup>71</sup>, MD, Lina Jonsson<sup>77</sup>, MSc, Rene S Kahn<sup>78</sup>, MD, PhD, John R. Kelsoe<sup>79</sup>, MD, James L. Kennedy<sup>73,80,81</sup>, MD, Tilo Kircher<sup>17</sup>, MD, Sarah Kittel-Schneider<sup>35,82</sup>, MD, Farah Klöhn-Saghatolislam<sup>1</sup>, MD, MBA, James A Knowles<sup>83,84</sup>, MD, PhD, Thorsten Manfred Kranz<sup>35</sup>, PhD, Trine Vik Lagerberg<sup>31,63</sup>, PhD, Mikael Landen<sup>77,85</sup>, MD, PhD, William B Lawson<sup>86</sup>, MD, Marion Leboyer<sup>75,76</sup>, MD, PhD, Qingqin S Li<sup>87</sup>, PhD, Mario Maj<sup>88</sup>, MD, PhD, Dolores Malaspina<sup>78,89</sup>, MD, MS, MSPH, Mirko Manchia<sup>90,91</sup>, MD, PhD, Fermin Mayoral<sup>74</sup>, PhD, MDF, Susan L McElroy<sup>92</sup>, MD, Melvin G McInnis<sup>93</sup>, MD, Andrew M McIntosh<sup>23</sup>, MD, FRCPsych, Helena Medeiros<sup>84</sup>, MSW, LICSW, Ingrid Melle<sup>27,28</sup>, MD, PhD, Vihra Milanova<sup>94</sup>, MD, PhD, Philip B. Mitchell<sup>95</sup>, MD, Palmiero Monteleone<sup>96</sup>, MD, Alessio Maria Monteleone<sup>88</sup>, MD, Markus M Nöthen<sup>47</sup>, MD, Tomas Novak<sup>97</sup>, PhD, John J Nurnberger<sup>98</sup>, MD, PhD, Niamh O'Brien<sup>6</sup>, PhD, Kevin S. O'Connell<sup>28,29</sup>, PhD, Claire O'Donovan<sup>99,100</sup>, MB BchBAO, Michael C O'Donovan<sup>54</sup>, PhD, MD, Nils Opel<sup>19</sup>, MD, Abigail Ortiz<sup>101,102</sup>, MSW, MPH, Michael J Owen<sup>54</sup>, PhD, MD, Erik Pålsson<sup>77</sup>, Carlos Pato<sup>84</sup>, MD, PhD, Michele T Pato<sup>84</sup>, MD, Joanna Pawlak<sup>57</sup>, PhD, MD, Julia-Katharina Pfarr<sup>17</sup>, M.Sc., Claudia Pisanu<sup>103</sup>, MD, James B. Potash<sup>59</sup>, MD, Mark H Rapaport<sup>104</sup>, MD, Daniela Reich-Erkelenz<sup>1</sup>, M.A., Andreas Reif<sup>35</sup>, MD, Eva Reininghaus<sup>40</sup>, MD, PhD, Jonathan Repple<sup>19</sup>, MD, Helène Richard-Lepouriel<sup>33</sup>, MD, Marcella Rietschel<sup>21</sup>, MD, Kai Ringwald<sup>17</sup>, M.Sc., Gloria Roberts<sup>95</sup>, PhD, Guy Rouleau<sup>105,106</sup>, MD, PhD, FRCPC, FRSC, Sabrina Schaupp<sup>1</sup>, M.Sc., William A Scheftner<sup>107</sup>, MD, Simon Schmitt<sup>17</sup>, 

- M.Sc., Peter R. Schofield<sup>65,66</sup>, PhD DSc, K Oliver Schubert<sup>50,108</sup>, MD, Eva C.

- Schulte<sup>1,2</sup>, MD, PhD, Barbara Schweizer<sup>59</sup>, R.N., B.S., Fanny Senner<sup>1,2</sup>, MD, Giovanni Severino<sup>103</sup>, MD, Sally Sharp<sup>6</sup>, PhD, Claire Slaney<sup>68</sup>, RN, Olav B. Smeland<sup>28,29</sup>, MD, PhD, Janet L Sobell<sup>109</sup>, PhD, Alessio Squassina<sup>99,103</sup>, Ph.D. MSci, Pavla Stopkova<sup>97</sup>, PhD, John Strauss<sup>73,80,81</sup>, MD, Alfonso Tortorella<sup>110</sup>, PhD, Gustavo
- Turecki<sup>45,111</sup>, MD, PhD, Joanna Twarowska-Hauser<sup>57</sup>, MD, PhD, Marin Veldic<sup>56</sup>, MD,
- Eduard Vieta<sup>39</sup>, MD, PhD, John B. Vincent<sup>73,80,81</sup>, PhD, Wei Xu<sup>112</sup>, PhD, Clement C. Zai<sup>73,80,81,113,114</sup>, PhD, Peter P. Zandi<sup>59</sup>, M.H.S., M.P.H., Ph.D., Maria Del
- Zompo<sup>32,103</sup>, MD, Psychiatric Genomics Consortium (PGC) BD Working Group,
- International Consortium on Lithium Genetics (ConLiGen), Colombia-US Cross
- Disorder Collaboration in Psychiatric Genetics, Arianna Di Florio<sup>54</sup>, PhD, MD, Jordan W. Smoller<sup>115,116</sup>, MD, Sc.D., Joanna M. Biernacka<sup>56,117</sup>, PhD, Francis J. McMahon<sup>118</sup>, MD, Martin Alda<sup>97,99</sup>, MD, Bertram Muller-Myhsok<sup>20</sup>, MD, Nikolaos Koutsouleris<sup>2,20,119</sup>, MD, Peter Falkai<sup>2</sup>, MD, Nelson B. Freimer<sup>4,120</sup>, MD, Till F.M. Andlauer<sup>121</sup>, PhD,<sup>+</sup> Thomas G Schulze<sup>1,21,30,122,123</sup>, MD,<sup>+</sup> Roel A. Ophoff<sup>4, 120,124</sup>,

- PhD.<sup>+</sup>

- AFFILIATION LIST AT THE END OF THE MANUSCRIPT
- \* joint first authors
  - <sup>†</sup> joint last authors

# **Corresponding Authors:**

### Janos L. Kalman, MD

- Institute of Psychiatric Phenomics and Genomics (IPPG),
- University Hospital, LMU Munich,
- Nussbaumstr. 7.
- D-80336 Munich, Germany
- Tel: +4989440053403
- Email: janos.kalman@med.uni-muenchen.de

#### Loes M. Olde Loohuis, PhD

- Center for Neurobehavioral Genetics
- Semel Institute for Neuroscience and Human Behavior.
- University of California Los Angeles,
- 760 Westwood Plaza,
- CA 90095 Los Angeles, USA
- Tel: +13107942723
- Email: loldeloohuis@mednet.ucla.edu
  - Running title: The genetics of disease onset in Bipolar Disorder
- **Keywords:** bipolar disorder, age at onset, polarity at onset, GWAS, polygenic score

Word count: 3711

# **RELEVANCE STATEMENT:**

In the largest study to systematically characterize age at onset (N=12977) and polarity at onset (N=6773) in bipolar disorder, we describe an association between illness onset characteristics and indicators of severity, confirming their clinical relevance. Our study shows that that early illness onset is associated with genetic liability for a broad range of psychiatric disorders. However, we also highlight systematic differences in age at onset across cohorts, continents, and phenotype definitions. This heterogeneity results in reduced heritability and affects genetic analyses, underscoring the need for the development of standardized phenotype definitions.

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

**Abstract** Background: Studying the phenotypic and genetic characteristics of age and polarity at onset (AAO, PAO) in bipolar disorder (BD) can provide new insights into disease pathology and facilitate the development of screening tools. Aims: To examine the genetic architecture of AAO and PAO and their association with BD disease characteristics. Methods: Genome-wide association studies (GWASs) and polygenic score (PGS) analyses of AAO (N=12977) and PAO (N=6773) were conducted in BD patients of 34 cohorts and a replication sample (N=2237). The association of onset with disease characteristics was investigated in two of these cohorts. **Results:** Earlier AAO was associated with an increased risk of psychotic symptoms, suicidality, and fewer episodes. A depressive onset correlated with lifetime suicidality and a manic onset with delusions and manic episodes. Systematic differences in AAO between cohorts and continents of origin were observed. This was also reflected in SNV-based heritability estimates, with higher heritabilities for stricter onset definitions. Increased polygenic scores for autism spectrum disorder (β=-0.34 years, SE=0.08), major depression ( $\beta$ =-0.34 years, SE=0.08), schizophrenia ( $\beta$ =-0.39 years, SE=0.08), and educational attainment ( $\beta$ =-0.31 years, SE=0.08) were associated with an earlier AAO. The AAO GWAS identified one significant locus, but this finding did not replicate. Neither GWAS nor PGS analyses yielded significant associations with PAO. Conclusions: AAO and PAO are associated with indicators of BD severity. Individuals with an earlier onset show an increased polygenic liability for a broad spectrum of psychiatric traits. Systematic differences in AAO across cohorts, continents, and phenotype definitions introduce significant heterogeneity, affecting analyses.

#### **MAIN TEXT**

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

# 1. Introduction

Bipolar disorder (BD) is highly heritable and affects approximately 1% of the population (1). It has a recurrent or chronic course and is associated with psychosocial impairment and reduced functioning, and it is a leading cause of global disease burden (2,3). Individuals usually experience their first (hypo)manic or depressive episode of BD in adolescence or early adulthood, but often they are not diagnosed until five to ten years later (4), especially in case of earlier age at onset or a depressive index episode (5). Early illness onset is associated with a more severe disease course and greater impairment across a wide range of mental and physical disorders and is a useful prognostic marker (6-9). However, pathophysiological processes leading to a disorder are thought to begin long before the first symptoms appear (10,11). Investigating the factors contributing to age and polarity (i.e., either a (hypo)manic or depressive episode) at onset could thus improve our understanding of disease pathophysiology and facilitate development of personalized screening and preventive measures. Accordingly, age and polarity at BD onset are considered as suitable phenotypes for genetic analyses. Genome-wide association studies (GWASs) have improved our understanding of the genetic architecture of susceptibility to BD; however, the genetic determinants of age and polarity at onset remain largely unknown. Evidence suggests that patients with an early age at onset carry a stronger genetic loading for BD risk (12). For example, an earlier parental age at onset increases familial risk for BD and is one of the strongest predictors of 5year illness onset in affected offspring (12-14). Thus far, GWASs for age at BD onset have been underpowered (15-17), and a study on 8610 cases found no significant evidence for a heritable component contributing to onset age (16).

Previous research suggested that a higher genetic risk burden for schizophrenia (SZ) may be associated with earlier age at onset of BD (16), but this finding was not replicated (18–20). Moreover, a recent study did not find an association of BD PGS with age at onset (21). Polarity of onset was shown to cluster in families (22), but the genetic architecture of polarity at onset has not yet been investigated. To fill these knowledge gaps, we performed comprehensive analyses of age and polarity at BD onset in the largest sample studied to date by (i) examining phenotype definitions and associations, (ii) conducting systematic GWASs, and (iii) investigating whether genetic load for neuropsychiatric disorders and traits contributes to age and polarity at BD onset.

### 2. Methods

# 2.1. Sample for the discovery GWAS

Participants with a BD diagnosis and age at onset information were selected from independent datasets, including those previously submitted to the Psychiatric Genomics Consortium (PGC) BD Working Group (18,23) and the International Consortium on Lithium Genetics (ConLiGen) (24). These consortia aggregate data from many cohorts worldwide. Our analyses comprised 34 cohorts with 12977 BD European ancestry cases from Europe, North America, and Australia. For a description of sample ascertainment, see the Supplementary Material. The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008. All procedures involving human subjects/patients were approved by the local ethics committees, and written informed consent was obtained from all subjects/patients.

### 2.1.1. Definition of age at onset

The definition of age at BD onset differed by cohort. To enhance cross-cohort comparability, we grouped the definitions into four broad categories (*Supplementary Table S1*): (1) *Diagnostic interview*: age at which the patient first experienced a (hypo)manic, mixed, or major depressive episode according to a standardized diagnostic interview; (2) *Impairment/help-seeking*: age at which symptoms began to cause subjective distress or impaired functioning or at which the patient first sought psychiatric treatment; (3) *Pharmacotherapy*: age at first administration of medication; (4) *Mixed*: a combination of the above-mentioned definitions. Across definitions, participants younger than eight years at onset were excluded (n=279) because of the uncertainty about the reliability of retrospective recall of early childhood onset.

The distribution of age at onset was highly skewed and differed greatly across the cohorts (*Table 1 and Fig. 1*). Therefore, we transformed age at onset in each cohort by rank-based inverse normal transformation and used this normalized variable as the primary dependent variable in all genetic analyses. To facilitate interpretability of effect sizes, we also report results of the corresponding untransformed age at onset.

### 2.1.2. Definition of polarity at onset

For each cohort, polarity at onset was defined by comparing the age at the first (hypo)manic and first depressive episode or using the polarity variable provided by the cohort. Specifically, patients were divided into three subgroups: (1) (hypo)mania before depression (PAO-M), (2) depression before (hypo)mania (PAO-D), and (3) mixed (PAO-X). The third category included patients with mixed episodes and those with a first (hypo)manic and depressive episode within the same year (*Table 1*). In the primary analysis, we combined (hypo)mania and mixed onset cases and

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

assigned this as the reference category. In secondary analyses, we excluded the mixed cases. 2.2. Disease characteristics We performed phenotypic analyses of disease onset in BD type I patients from three cohorts: the Dutch Bipolar cohort (N=1313) (25) and the German PsyCourse (26) and FOR2107 (27) cohorts, which were analyzed jointly (N=346). We analyzed the following disease characteristics, which were previously reported as being associated with disease onset and were assessed in a similar way across cohorts (28): lifetime delusions, lifetime hallucinations, history of suicide attempt, suicidal ideation, current smoking, educational attainment, living together with a partner, and frequency of manic and depressive episodes per year. For more detailed information, see the Supplementary Material and Supplementary Table S9. 2.3. Genetic analyses We analyzed age at onset in 34 cohorts comprising 12977 BD patients. We performed a GWAS on these cohorts and attempted to replicate any findings in a GWAS on six additional cohorts with 2237 BD patients. For details on the datasets, including phenotype definitions and distributions, see Table 1, Fig. 1, and Supplementary Table S1. 2.3.1. Genotype data quality control and imputation Cohorts were genotyped according to local protocols. Individual genotype data of all discovery-stage cohorts were processed with the PGC Rapid Imputation and Computational Pipeline for GWAS (RICOPILI) (29) with the default parameters for standardized quality control (QC), imputation, and analysis. Before imputation,

filters for the removal of variants included non-autosomal chromosomes,

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

missingness ≥0.02, and a Hardy-Weinberg equilibrium test P <1×10<sup>-10</sup>. Individuals were removed if they showed a genotyping rate ≤0.98, absolute deviation in autosomal heterozygosity of  $F_{het} \ge 0.2$ , or a deviation >4 SDs from the mean in any of the first eight multidimensional scaling (MDS) ancestry components within each cohort. From genetic duplicates (assessed with the genetic identity-by-state matrix) and relatives (pi-hat >0.2) across all samples, only the case with more complete phenotypic information on AAO and PAO, sex, and diagnosis was retained. Imputation was performed by IMPUTE2 with the Haplotype Reference Consortium reference panel (30). 2.3.2. Genome-wide association studies We conducted separate GWASs for all cohorts containing 40 or more individuals in RICOPILI/PLINK (29,31), with sex, BD subtype, and the first eight ancestry components as covariates. Sample sizes are provided in Supplementary Tables S2, S7. The results showed no inflation of test statistics (Supplementary Table S2). We combined the GWASs in METAL by fixed-effects meta-analysis (32). The primary analyses were transformed age at onset (analyzed by linear regression), and polarity at onset (analyzed by logistic regression). Secondary analyses included GWASs stratified by age at onset definition and continent of origin. For the meta-analysis summary statistics, we applied the following variant-level post-QC parameters: imputation INFO score ≥0.9, MAF ≥0.05, and successfully imputed/genotyped in □ more than □ half of the cohorts. We estimated power to replicate our original GWAS finding using the pwr package in R. Given the parameters from the locus identified through our discovery GWAS (beta =0.075, allele frequency =0.32) and a standardized phenotype, we had 76% power

261 to detect the effect in our sample size of 2237 at an alpha level of 0.1. For

comparison, we had 57% power to detect the effect in our discovery sample.

2.3.3. Polygenic Scoring

263

265

267

268

269

270

271

272

276

277

278

279

280

281

283

284

264 We calculated polygenic scores (PGS) based on prior GWAS of Attention-

Deficit/Hyperactivity Disorder (ADHD) (33), Autism Spectrum Disorder (ASD) (34),

266 BD (18), Educational Attainment (EA, measured as "years in education") (35), Major

Depression (MD) (36), and schizophrenia (37) (Supplementary Table S3). PGS

weights were estimated with PRS-CS (38), with six scores per genome-wide

association study (GWAS; with  $\varphi = 1 \times 10^{-1}$ ,  $1 \times 10^{-2}$ ,  $1 \times 10^{-3}$ ,  $1 \times 10^{-4}$ ,  $1 \times 10^{-5}$ , and

1x10<sup>-6</sup>). We tested the associations of the PGS with the AAO and PAO by linear and

logistic regressions, respectively, with the same covariates as in the GWAS

analyses. The significance threshold was Bonferroni-corrected for 96 tests (a

 $= 0.05/[6 \varphi \text{ thresholds} \times 8 \text{ traits} \times 2 \text{ phenotypes}] = 5.2 \times 10^{-4}).$ 

274 2.3.3. Heritability analyses

We assessed the variance in age and polarity at onset explained by genotyped

variants (single-nucleotide variant [SNV]-based heritability,  $h^2_{SNV}$ ). For individual

cohorts with more than 1000 samples, we estimated  $h^2_{SNV}$  with GCTA GREML

(39,40). Here, we validated the robustness of the  $h^2_{SNV}$  estimate with the mean of

1000x resampling of 95% of the sample. For meta-analysis summary statistics with

sample sizes >3000, we estimated  $h^2_{SNV}$  by linkage disequilibrium (LD) score

regression (41). The 95% CIs were constrained to a minimum of 0 and a maximum

282 of 1.

# 3. Results

### 3.1. Heterogeneity of age and polarity at onset across cohorts

Among the four definitions of age at onset across the 34 cohorts, impairment/helpseeking was the most common in Europe and diagnostic interview the most common in North America (Table 1, Fig. 1A-B). Across cohorts, the median age at onset was 21 years (range of medians: 16-30 years; Fig. 1A-B). The median untransformed age at onset differed significantly between BD subtypes (type I, 21 years; type II, 22 years; Kruskal-Wallis test  $P=1.8\times10^{-4}$ ; Supplementary Table S6), age at onset definitions (diagnostic interview, 19 years; impairment/help-seeking, 23 years; pharmacotherapy, 30 years; mixed, 22 years;  $P=2.96\times10^{-191}$ ), and continent of origin (Europe, 24 years; North America, 18 years; and Australia, 19.5 years; P=2.0×10<sup>-1</sup> <sup>263</sup>). These differences across continents remained significant when including onset definitions and BD subtype in a multivariable regression model, indicating that they differences not entirely driven bγ between diagnostic instruments are (Supplementary Table S6). The majority of patients had a depression-first polarity at onset in both Europe and North America (57% and 59%, respectively; P=0.17 test of proportion). Depressionfirst cases were less frequent in the impairment/help-seeking than in the diagnostic interview category (55% and 60%, respectively; *P*=4.5×10<sup>-4</sup>, *Supplementary Fig. S1*).

#### SUGGESTED POSITION OF TABLE 1 and FIGURE 1

#### 3.2. Analyses of disease characteristics

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

In a meta-analysis of the Dutch and German samples, earlier age at onset was significantly associated with a higher probability of lifetime delusions, hallucinations, suicide attempts, suicidal ideation, lower educational attainment, and not living together (Table 2, Supplementary Tables S4 and S5). Later age at onset was positively significantly correlated with a higher number of manic and depressive

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

episodes per year (see secondary analyses in the Supplementary Material). Moreover, a (hypo)manic onset was significantly associated with a greater likelihood of delusions and more manic episodes per year, whereas a depressive onset was associated with a higher probability of suicidal ideation and lifetime suicide attempts. SUGGESTED POSITION OF TABLE 2 3.3. Genome-wide association studies In our GWAS meta-analysis of age at onset using all 34 cohorts, one locus reached genome-wide significance (rs1610275 on chromosome 16; minor allele G frequency=0.319,  $\beta$ =0.075 SDs, SE=0.014, P=3.39×10<sup>-8</sup>, Fig. 2A, Supplementary Table S7. Supplementary Fig. S2). This SNV mapped to an intron of the brainexpressed gene FTO (alpha-ketoglutarate dependent dioxygenase, Fig. 2B). However, this association was not replicated in an independent sample of six cohorts (Supplementary Table S7, Supplementary Fig. S2). In this replication sample (N=2237), we had 76% power to replicate this SNV at P=0.1. In the GWAS of polarity at onset, no variant was genome-wide significant in either primary (PAO-M/-X vs PAO-D) or secondary (PAO-M vs PAO-D) analyses (Supplementary Fig. S3). We calculated PGSs for age and polarity at onset using leave-one-out summary statistics from these GWASs. The age-at-onset PGS was nominally significantly associated with age at onset ( $\beta$ =0.23 years, SE=0.08, P=0.0087,  $\varphi$ =0.1, Fig. 2C-D) for five of six tested φ parameters but did not withstand correction for multiple testing (Supplementary Table S8). The polarity-at-onset PGS was not associated with the polarity at onset (Supplementary Fig. S4).

SUGGESTED POSITION OF FIGURE 2

3.4. SNV-based heritability of the investigated phenotypes

Using the GWAS summary statistics, we estimated the SNV-based heritability  $h^2_{SNV}$  by LD score regression (Fig. 1C). We estimated  $h^2_{SNV}$  directly from genotype data in the only cohort large enough for this analysis,  $wtccc\ h^2_{SNV}$ =0.63, P=0.0026) and validated the robustness of this estimate by resampling ( $h^2_{SNV}$ =0.62, resampling 95% CI=0.15-1.00). The  $h^2_{SNV}$  estimates decreased when cohorts, phenotype definitions, and continents were combined (e.g., "diagnostic interview" in North America:  $h^2_{SNV}$ =0.16 [95% CI=0-0.40], "impairment/help seeking" in Europe:  $h^2_{SNV}$ =0.03 [95% CI=0-0.25], all combined  $h^2_{SNV}$ =0.05 [95% CI=0-0.12]). Because the sample sizes were smaller, we could not estimate the  $h^2_{SNV}$  of impairment/help seeking in North America and diagnostic interview in Europe. For depressed vs. (hypo)manic and mixed polarity at onset,  $h^2_{SNV}$  was 0.17 (95% CI=0.05-0.29) on the observed scale.

# 3.5. Associations of PGSs with age and polarity at onset

We analyzed whether PGSs for five psychiatric disorders and EA were associated with earlier age at onset (*Fig. 2C-D, Supplementary Table S8*). After correcting for 96 tests, higher PGSs for ASD ( $\beta$ =-0.34 years per 1 SD increase in PGS, SE=0.08, P=9.85×10<sup>-6</sup>), MD ( $\beta$ =-0.34, SE=0.08, P=1.40×10<sup>-6</sup>), SZ ( $\beta$ =-0.39, SE=0.08, P=2.91×10<sup>-6</sup>), and EA ( $\beta$ =-0.31, SE=0.08, P=5.58×10<sup>-5</sup>) were significantly associated with an earlier BD age at onset. This was not the case for ADHD or BD PGS. No PGS was significantly associated with polarity at onset (*Supplementary Fig. S4, Supplementary Table S8*).

# 4. Discussion

Our study represents the largest and most comprehensive characterization of disease onset in BD to date. It highlights the clinical relevance of age and polarity at

onset in BD by demonstrating how these phenotypes are associated with several indicators of illness severity. We found that higher PGS for ASD, MD, SZ, and EA were associated with an earlier age at onset. Thereby we demonstrated that the BD age at onset has a polygenic etiology. Individuals with an earlier age at onset harbor increased genetic liability for a broad spectrum of psychiatric disorders and related traits. However, we show significant heterogeneity of age at onset (and, partly, polarity at onset) across cohorts, continents, and age-at-onset definitions and demonstrate the challenges for genetic analyses that occur in the presence of substantial phenotypic heterogeneity. First, heritability estimates differed for criteria used to define age at onset and decreased when combining multiple cohorts. Second, a single genome-wide significant variant, identified in the age-at-onset discovery GWAS, did not replicate in an independent dataset.

A striking finding of our study was the systematic difference in the age at onset distribution across cohorts, continents, and assessment strategies. The definition of age at onset correlated strongly with the continent, with diagnostic interview being mainly used in North America and impairment/help-seeking in Europe. Using multivariable regression, we showed that the continent-level differences cannot fully be explained by the age-at-onset assessment strategy and that both factors contribute significantly to the heterogeneity (Supplementary Table S6) (4). However, variations in the demographic structure of analyzed populations may have biased the assessed age at onset of BD, contributing to the observed differences (42). Although prior research has identified age at onset differences across continents (e.g., the incidence of early onset BD is higher in the US than in Europe (43,44)), this study is the first to systematically assess this heterogeneity

across many cohorts with different ascertainment strategies and demonstrate how it may reduce statistical power in genetic analyses.

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

Interestingly, these systematic differences in age at onset phenotypes are reflected in heritability estimates: We observed the highest SNV-based heritability  $h_{SNV}^2$  when onset was established by diagnostic interview and the lowest when it was captured with more health system-specific and subjective measurements, such as item 4 of the Operational Criteria Checklist for Psychotic Illness (impairment/helpseeking). Moreover,  $h^2_{SNV}$  estimates approached zero when all samples were combined in our primary analysis (h<sup>2</sup><sub>SNV</sub>=0.05; 95% Cl=0-0.12), underscoring the strong impact of phenotypic heterogeneity. Thus, we not only showed systematic heterogeneity in a clinically relevant psychiatric phenotype across cohorts but also provided direct evidence for how this heterogeneity can hamper genetic studies. Notably, a recent investigation demonstrated that the phenotyping method (e.g., diagnostic interview vs. self-report) significantly influenced heritability estimates, GWAS results, and PGS performance in analyses of MD susceptibility, with broader phenotype definitions resulting in lower heritability estimates (45). Nevertheless, the significant results in our PGS association analyses confirmed that a significant genetic component of age at onset exists.

For polarity at disease onset, the relative proportion of patients reporting a depressive index episode did not differ across continents but did differ across instruments, i.e., a (hypo)manic onset was more common if age at onset was based on impairment/help-seeking instead of diagnostic interview.

Although our discovery GWAS identified a genome-wide significant locus for age at onset, the lack of replication suggests that this finding may have been a false-positive. Of note, our replication power analysis did not account for the phenotypic

and genetic heterogeneity across the cohorts and may thus have underestimated the necessary sample size. Moreover, the replication sample was more ethnically diverse than the discovery sample, reducing statistical power. While the effect of the age at onset PGS on the trait measure itself was substantial (0.23 years per 1 SD change in the PGS), the association was only nominally significant.

Possibly, the rank-based inverse-normal transformation of the age at onset affected the GWAS and heritability analyses. We conducted this transformation because, first, the original age at onset distribution was highly skewed and thus not suitable for linear regression and, second, the age at onset differed significantly between cohorts, which could have biased the meta-analysis. By transforming the data, however, only the rank and not the absolute differences in onset between patients was maintained, reducing interpretability of the phenotype and the genetic effects.

Higher PGSs for SZ, MD, ASD, and EA were significantly associated with a lower age at onset, confirming a genetic component for age at onset. This finding supports the hypothesis that earlier age of onset, in addition to potentially being driven by onset-specific modifier genes, is influenced by a transdiagnostic liability for psychiatric disorders. In contrast to several other disorders (e.g. multiple sclerosis and late-onset Alzheimer's disease), where the strongest genetic risk factors for disease liability were also the most important genetic factors associated with earlier disease onset (8,46), we did not find a significant association between BD PGS and age at BD onset, confirming a previous study (21). Importantly, the sample sizes of both the SZ and MD GWASs were larger than those of the BD GWAS, improving the predictive power of these PGSs compared to the BD PGS.

Our finding of a significant relationship of higher EA PGS with an earlier age at onset may seem counterintuitive. However, several studies found a significant association between higher EA and BD (47,48). In addition, a recent study demonstrated a positive genetic correlation and causal relationship between high EA and BD (49). Our findings show that high EA is not only a risk factor for BD but is also associated with an earlier onset.

In our analyses of polarity at onset, the small sample size and dichotomous phenotype reduced statistical power. None of the tested PGSs were significantly associated with polarity at onset, and the GWAS did not identify genome-wide significant loci. However, we observed significant  $h^2_{SNV}$  estimates for PAO-M/-X vs. PAO-D, providing substantial evidence that genetic factors contribute to the polarity at BD onset.

The success of GWASs in the study of complex, polygenic traits relies on ever larger sample sizes and harmonized phenotype definitions and analysis techniques (50). As previously shown for depression (45), our study suggests that heterogeneity of phenotype definitions decreases the ability to identify genetic risk profiles that contribute to clinically relevant BD phenotypes. In addition to phenotype definitions, other factors that may limit cross-cohort comparability of the assessed phenotypes include demographic differences, cultural differences in diagnostic practice, and the uncertainty and measurement errors associated with recall bias, limited interrater reliability, and differences across health care systems (43,51–53). In our study, we performed both SNV-level and risk score associations using a structured meta-analysis, which mitigates some of the noise introduced by phenotypic heterogeneity. However, we are unable to account for differences in underlying genetic etiology of

the phenotypes across cohorts. This heterogeneity is an important limitation of our study and should be considered in future phenotype analyses.

Our phenotype analyses confirmed the clinical relevance of disease onset phenotypes in BD. Age at BD onset was associated with important illness severity indicators, such as suicidality, positive symptoms, and achieving a lower level of education, thereby replicating findings of previous studies (25,28,54). Furthermore, patients with a depressive BD onset had an increased probability of lifetime suicidality, while those with a (hypo)manic onset were more likely to experience delusions and manic episodes (55–57). Contrary to previous evidence in a US (but not a French) sample, we observed that an earlier onset was associated with fewer episodes per illness year (56). Of note, when not normalizing for the illness duration, the age at onset was positively correlated with the number of episodes.

#### 4.1. Conclusion

Phenotypes of BD onset are clinically important trait measures that represent the well-known clinical and biological heterogeneity of this severe psychiatric disorder. Genetic analysis of age and polarity at onset may lead to a better understanding of the biological risk factors underlying mental illness and support clinical assessment and prediction. Our study provides significant evidence of a genetic contribution to age and polarity at BD onset but also demonstrates the need for systematic harmonization of clinical data on BD onset in future studies. The coordinated efforts of international consortia and our growing ability to harness the rich phenotypic information stored in electronic health records will provide an unprecedented pool of phenotypic information on an increasingly diverse patient population (58–60). We expect that future genetic studies of age and polarity at

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

onset will make major contributions toward our understanding of the etiology of BD and other psychiatric disorders. 5. Author contributions Concept and design: Kalman, Olde Loohuis, Vreeker, Andlauer, Schulze, and Ophoff. Analysis and interpretation of data: Kalman, Olde Loohuis, Vreeker, Andlauer Drafting of the manuscript: Kalman, Olde Loohuis, Vreeker, Andlauer Supervision, and critical revision of the manuscript: Schulze, Ophoff, McMahon, Smoller, Alda. All other authors provided data, contributed ideas and suggestions for analyses, interpreted results and revised the final manuscript. 6. Acknowledgments The authors thank Jacquie Klesing, Board-certified Editor in the Life Sciences (ELS), for editing assistance with the manuscript. BOMA-Australia sample: We thank Gin Mahli, Colleen Loo, and Micheal Breaskpear for their contribution to clinical assessments of a subset of patients and also Andrew Frankland for his work in collating clinical record data.

WTCCC sample: This study makes use of data generated by the Wellcome Trust Case-Control Consortium. A full list of the investigators who contributed to the generation of the data is available from www.wtccc.org.uk.

French sample: We thank the psychiatrists and psychologists who participated in the clinical assessment of patients in France (C. Henry, S. Gard, JP Kahn, L Zanouy, RF Cohen and O. Wajsbrot-Elgrabli) and thank the patients for their participation.

# 7. Funding

- 510 Loes M. Olde Loohuis: NIH K99/R00 MH116115.
- 511 Eli Stahl: NIH U01MH109536; E.S. is now employed by the Regeneron Genetics
- 512 Center.

- 513 Andrew McQuillin: Medical Research Council, Grant/Award Numbers: G0500791,
- 514 G0701007, G0801038, G1000708, G9623693N; Stanley Center for Psychiatric
- 515 Research at the Broad Institute
- 516 Douglas Ruderfer: R01MH116269
- 517 Maria Grigoroiu-Serbanescu: UEFISCDI, Romania, several grants
- 518 Tim B Bigdeli: NIH MH085548, MH085542, MH104564
- 519 Fabian Streit: BMBF grant 01EW1810 ERA-Net Neuron "Synschiz", BMBF grant
- 520 01ZX1614G e:Med Integrament
- Mark J Adams: Wellcome Trust 104036/Z/14/Z, MRC MC PC 17209
- 522 Rolf Adolfsson: Swedish Research Council (2009-33891-68296-196) and the
- 523 Swedish Federal Government under the LUA/ALF agreement (ALF; RV-161691)
- 524 Ole A. Andreassen: Norwegian Research Council, KG Jebsen Stiftelsen, South-
- 525 Eastern Norway Health Authority
- 526 Ceylan Balaban: BMBF "BipoLife" Subproject TPP1
- 527 Frank Bellivier: INSERM (Institut National de la Sante et de la Recherche Medicale -
- 528 C0829), AP-HP (Assistance Publique des Hopitaux de Paris RBM0436), Fondation
- 529 FondaMental (RTRS Sante Mentale), Labex Bio-PSY (Investissements dAvenir
- 530 program managed by the ANR under reference ANR-11-IDEX- 0004-02).
- 531 Antonio Benabarre: Thanks the support of the Spanish Ministry of Science and
- 532 Innovation (PI17/01122)
- 533 Wade Berrettini: R01 MH078156

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

Evelyn J Bromet: NIH MH085548, MH085542, MH104564 Sven Cichon: European Union Horizon 2020 Research and Innovation Programme (grant 785907 (HBP SGA2)), BMBF grant 01ZX1314Ae:Med Integrament, Swiss National Science Foundation (SNSF) grant 156791 William Coryell: R01 MH078154 Nick Craddock: Wellcome Trust (grant #078901) David Craig: R01 MH078159 Paul E. Croarkin: National Institue of Mental Health (NIMH) R01 MH113700 Udo Dannlowski: This work was funded by the German Research Foundation (DFG, grant FOR2107 DA1151/5-1 and DA1151/5-2 to UD; SFB-TRR58, Projects C09 and Z02 to UD) and the Interdisciplinary Center for Clinical Research (IZKF) of the medical faculty of Munster (grant Dan3/012/17 to UD). Franziska Degenhardt: German Federal Ministry of Education and Research (BMBF) within the e:Med programme (grant COMMITMENT) and the EU COST (European Cooperation in Science and Technology) programme (COST Action EnGagE CA17130). Bruno Etain: INSERM (Institut National de la Sante et de la Recherche Medicale -C0829), AP-HP (Assistance Publique des Hopitaux de Paris - RBM0436), Fondation FondaMental (RTRS Sante Mentale), Labex Bio-PSY (Investissements dAvenir program managed by the ANR under reference ANR-11-IDEX- 0004-02). Ayman H Fanous: NIH MH085548, MH085542, MH104564 Janice M. Fullerton: National Health and Medical Research Council (Australia) grants 1037196,1063960, 1066177; and The Janette Mary ONeil Research Fellowship Julie Garnham: Canadian Institutes of Health Research (grant #166098); Dalhousie Medical Research Foundation, Genome Atlantic, Lindsay family fund

559 Elliot Gershon: R01 MH078153 560 Tim Hahn: TH was supported by the German Research Foundation (DFG grants 561 HA7070/2-2, HA7070/3, HA7070/4) and the Interdisciplinary Center for Clinical 562 Research (IZKF) of the medical faculty of Munster (MzH3/020/20). 563 Stephane Jamain: INSERM (Institut National de la Sante et de la Recherche 564 Medicale - C0829), AP-HP (Assistance Publique des Hopitaux de Paris - RBM0436), 565 Fondation FondaMental (RTRS Sante Mentale), Labex Bio-PSY (Investissements 566 dAvenir program managed by the ANR under reference ANR-11-IDEX- 0004-02). 567 Esther Jimenez: EJ thanks the support of the Spanish Ministry of Science and 568 Innovation (PI15/00283, PI18/00805) integrated into the Plan Nacional de I+D+I and 569 co-financed by the ISCIII-Subdireccin General de Evaluacin and the Fondo Europeo 570 de Desarrollo Regional (FEDER); the Instituto de Salud Carlos III; the CIBER of 571 Mental Health (CIBERSAM); the Secretaria dUniversitats i Recerca del Departament 572 dEconomia i Coneixement (2017 SGR 1365), the CERCA Programme, and the 573 Departament de Salut de la Generalitat de Catalunya for the PERIS grant 574 SLT006/17/00357. 575 Ian Jones: Wellcome Trust (grant #078901) 576 Lisa Jones: Wellcome Trust (grant #078901) 577 John R. Kelsoe: R01 MH078151 578 Tilo Kircher: This work was funded by the German Research Foundation (DFG, grant 579 FOR2107 KI588/14-1 and FOR2107 KI588/14-2 to TK) 580 George Kirov: Recriutment of the Bulgarian Trios was funded by the Janssen 581 Research Foundation 582 James A Knowles: NIH MH085548, MH085542, MH104564 583 Thorsten Kranz: BMBF "BipoLife" Subproject TPP1

- Trine Vik Lagerberg: Norwegian Research Council (grant #288542)
- 585 Mikael Landen: The Stanley Center for Psychiatric Research, Broad Institute from a
- grant from Stanley Medical Research Institute, the Swedish Research Council (2018-
- 587 02653), the Swedish foundation for Strategic Research (KF10-0039), the Swedish
- 588 Brain foundation (FO2020-0261), and the Swedish Federal Government under the
- 589 LUA/ALF agreement (ALF 20170019, ALFGBG-716801).
- 590 William Lawson: R01 MH078161
- Marion Leboyer: INSERM (Institut National de la Sante et de la Recherche Medicale
- 592 C0829), AP-HP (Assistance Publique des Hopitaux de Paris RBM0436),
- 593 Fondation FondaMental (RTRS Sante Mentale), Labex Bio-PSY (Investissements
- dAvenir program managed by the ANR under reference ANR-11-IDEX- 0004-02).
- 595 Dolores MAlaspina: NIH MH085548, MH085542, MH104564
- 596 Melvin McInnis: R01 MH078162
- 597 Andrew M McIntosh: Wellcome Trust 104036/Z/14/Z, MRC MC\_PC\_17209
- 598 Helena Medeiros: NIH MH085548, MH085542, MH104564
- 599 Ingrid Melle: "Regional Health Authority South-Eastern Norway (grants #
- 600 2015088,2018093)"
- Vihra Milanova: Recriutment of the Bulgarian Trios was funded by the Janssen
- Research Foundation
- 603 Philip B. Mitchell: National Health and Medical Research Council (Australia) grants
- 604 1037196, 1177991
- John Nurnberger: R01 MH078152
- 606 Carlos Pato: NIH MH085548, MH085542, MH104564
- 607 Michele T Pato: NIH MH085548, MH085542, MH104564
- 608 James B. Potash: R01 MH078157

- 609 Mark H Rapaport: NIH MH085548, MH085542, MH104564 610 Andreas Reif: BMBF "BipoLife" Subproject TPP1 611 Marcella Rietschel: BMBF grant 01EW1810 ERA-Net Neuron "Synschiz", BMBF 612 grant 01EW1904 ERA-Net Neuron "Embed", BMBF grant 01ZX01909A e:Med 613 SysmedSUD, BMBF grant 01ZX1614G e:Med Integrament 614 Gloria Roberts: National Health and Medical Research Council (Australia) grants 615 1037196 616 Guy Rouleau: Canadian Institutes of Health Research (grant #166098) 617 William A. Scheftner: R01 MH078155 618 Peter R. Schofield: National Health and Medical Research Council (Australia) grants 619 1037196,1063960, 1176716 620 Janet L Sobell: NIH MH085548, MH085542, MH104564 621 John Strauss: Canadian Institutes of Health Research, MOP-172013 622 Gustavo Turecki: Canadian Institutes of Health Research (grant #166098) 623 Eduard Vieta: EV thanks the support of the Spanish Ministry of Science and 624 Innovation (PI15/00283, PI18/00805) integrated into the Plan Nacional de I+D+I and 625 co-financed by the ISCIII-Subdireccin General de Evaluacin and the Fondo Europeo 626 de Desarrollo Regional (FEDER); the Instituto de Salud Carlos III; the CIBER of 627 Mental Health (CIBERSAM); the Secretaria dUniversitats i Recerca del Departament 628 dEconomia i Coneixement (2017 SGR 1365), the CERCA Programme, and the 629 Departament de Salut de la Generalitat de Catalunya for the PERIS grant 630 SLT006/17/00357. 631 John B. Vincent: Canadian Institutes of Health Research, MOP-172013
- Jordan W Smoller: R01MH063445

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

656

657

Francis J. McMahon: Funded in part by the Intramural Research Program of the NIMH (ZIA MH002843) Martin Alda: Canadian Institutes of Health Research (grant #166098); Dalhousie Medical Research Foundation, Genome Atlantic, Lindsay family fund Till. F. M. Andlauer: German Federal Ministry of Education and Research (BMBF) through the DIFUTURE consortium of the Medical Informatics Initiative Germany (grant 01ZZ1804A) and the Integrated Network IntegraMent, under the auspices of the e:Med Programme (grant 01ZX1614J), as well as the European Unions Horizon 2020 Research and Innovation Programme (grant MultipleMS, EU RIA 733161) The Collection of the Dutch cohort was funded through NIMH R01MH090553 awarded to Dr. Ophoff. The collection of the Colombian samples was funded through NIMH R01 MH113078 awarded to Drs. Lopez-Jaramillo, Bearden and Freimer. The collection of the BOMA-Australia sample (bip\_bmau\_eur) was supported by the Australian National Medical and Health Research Council (NHMRC) Program Grant 1037196 and Project Grants 1063960 and 1066177. DNA was extracted by Genetic Repositories Australia, an Enabling Facility that was supported by NHMRC Enabling Grant 401184. We gratefully acknowledge the Janette Mary ONeil Research Fellowship (to JMF). We acknowledge support from NHMRC Investigator Grants (Leadership 3) to PBM (1177991) and PRS (1176716). Funding for the project was provided by the Wellcome Trust under award 076113, 085475 and 090355. The work by the French group was supported by INSERM (Institut National de la Sante et de la Recherche Medicale - C0829), AP-HP (Assistance Publique des Hopitaux de Paris - RBM0436), the Fondation FondaMental (RTRS Sante Mentale),

- and the labex Bio-PSY (Investissements dAvenir program managed by the ANR
- under reference ANR-11-IDEX- 0004-02).

#### 8. Declaration of Interest

- Amare T. Azmeraw: Dr Amare has received 2020-2022 NARSAD Young Investigator
- 663 Grant from the Brain & Behaviour Research Foundation.
- 664 Ole A. Andreassen: Speaker's honorarium Sunovion, Lundbeck. Consultant
- 665 HealthLytix

- 666 Bernhard Baune: Honoraria: Lundbeck, Janssen, LivaNova, Servier
- 667 Carrie Bearden: Novartis Scientific Advisory Board
- 668 Clark Scott: Honoraria and Investigator Initiated project funding from Jannsen-Cilag
- 669 Australia, Lundbeck-Otsuka Australia
- J. Raymond DePaulo: owns stock in CVS Health; JRD was unpaid consultant for
- Myriad Neuroscience 2017 & 2019
- 672 Michael C. O'Donovan: Research unrelated to this manuscript supported by a
- 673 collaborative research grant from Takeda Pharmaceuticals
- 674 Bruno Etain: Honoraria for Sanofi
- 675 Mark A. Frye: Grant Support Assurex Health, Mayo Foundation, Medibio Consultant
- 676 (Mayo) Actify Neurotherapies, Allergan, Intra-Cellular Therapies, Inc., Janssen,
- 677 Myriad, Neuralstem Inc., Sanofi, Takeda, Teva Pharmaceuticals
- Per Hoffmann: Employee of Life&Brain GmbH, Member of the Scientific Advisory
- 679 Board of HMG Systems Engeneering GmbH
- 680 Mikael Landen: Speaker's honoraria Lundbeck pharmaceuticals
- Andrew M McIntosh: Research funding from The Sackler Trust, speaker fees from
- 682 Illumina and Janssen
- 683 Philip B. Mitchell: Remuneration for lectures in China on bipolar disorder research by
- 684 Sanofi (Hangzhou)
- John Nurnberger: Investigator for Janssen

- 686 Benjamin M. Neale: Is a member of the scientific advisory board at Deep Genomics
- 687 and RBNC Therapeutics. A consultant for Camp4 Therapeutics, Takeda
- 688 Pharmaceutical and Biogen.
- 689 Andreas Reif: Speaker's honoraria / Advisory boards: Janssen, Shire/Takeda,
- 690 Medice, SAGE and Servier
- 691 Eli Stahl: now employed by the Regeneron Genetics Center.
- Kato Tadafumi: Honoraria: Kyowa Hakko Kirin Co., Ltd., Eli Lilly Japan K.K., Otsuka
- 693 Pharmaceutical Co., Ltd., GlaxoSmithKline K.K., Taisho Pharma Co., Ltd., Taisho
- 694 Pharmaceutical Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Dainippon
- 695 Sumitomo Pharma Co., Ltd., Meiji Seika Pharma Co., Ltd., Pfizer Japan Inc.,
- 696 Mochida Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Janssen Pharmaceutical
- 697 K.K., Janssen Asia Pacific, Yoshitomiyakuhin, Astellas Pharma Inc., Nippon
- 698 Boehringer Ingelheim Co. Ltd., MSD K.K., Kyowa Pharmaceutical Industry Co., Ltd.,
- Takeda Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Eisai Co.,
- 700 Ltd. Grants: Takeda Pharmaceutical Co., Ltd., Dainippon Sumitomo Pharma Co.,
- 701 Ltd., Otsuka Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Eisai Co., Ltd.,
- 702 Mitsubishi Tanabe Pharma Corporation.
- 703 Eduard Vieta: Has received grants and served as consultant, advisor or CME
- speaker for the following entities: AB-Biotics, Abbott, Allergan, Angelini, Dainippon
- 705 Sumitomo Pharma, Ferrer, Gedeon Richter, Janssen, Lundbeck, Otsuka, Sage,
- 706 Sanofi-Aventis, Sunovion, and Takeda.
- None of the other Authors reported any biomedical financial interests or potential
- 709 conflicts of interest.

### 9. Availability of results

711

714

715 716

717

- 712 Summary statistics for our meta-analysis of the GWAS cohort samples are available
- through the PGC (https://www.med.unc.edu/pgc/download-results/). 713

# 10. Author details (affiliations)

- <sup>1</sup> Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU 718
- Munich, Munich, Germany 719
- <sup>2</sup> Department of Psychiatry and Psychotherapy, University Hospital Munich 720
- 721 <sup>3</sup> International Max Planck Research School for Translational Psychiatry, Munich, 722 Germany
- 723 <sup>4</sup> Center for Neurobehavioral Genetics, Semel Institute for Neuroscience and Human
- 724 Behavior, University of California Los Angeles, Los Angeles, USA
- 725 <sup>5</sup> Department of Child and Adolescent Psychiatry and Psychology, Erasmus MC, The 726 Netherlands
- <sup>6</sup> Division of Psychiatry, University College London, London, GB 727
- <sup>7</sup> Division of Psychiatric Genomics, Mount Sinai School of Medicine, New York NY 728 729
- 730 Division of Genetic Medicine, Department of Medicine, Vanderbilt Genetics 731 Institute, Vanderbilt University Medical Center
- <sup>9</sup> Department of Biomedical Informatics, Vanderbilt University Medical Center 732
- 733 Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical 734 Center
- <sup>11</sup> Alexandru Obregia Clinical Psychiatric Hospital, Bucharest, Romania 735
- <sup>12</sup> Department of Psychiatry and Psychotherapy, Charite Universitätsmedizin 736
- <sup>13</sup> Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston 737 738 MA 02114, USA
- <sup>14</sup> Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, 739 740 Cambridge MA 02142, USA
- Department of Psychiatry and Behavioral Sciences, SUNY Downstate Health 741 Sciences University, Brooklyn, NY, US

  16 VA NY Harbor Healthcare System, Brooklyn, NY, US 742
- 743
- 17 744 Department of Psychiatry and Psychotherapy, Philipps-University Marburg, 745 Germany
- <sup>18</sup> Center for Mind, Brain and Behavior (CMBB), Marburg, Germany 746
- <sup>19</sup> University of Munster, Department of Psychiatry 747
- <sup>20</sup> Max Planck Institute of Psychiatry, Munich, Germany 748
- <sup>21</sup> Department of Genetic Épidemiology in Psychiatry, Central Institute of Mental 749
- Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany 750
- Centro de Investigación Biomedica en Red de Salud Mental (CIBERSAM), 751 752 Barcelona, Spain.
- <sup>23</sup> Division of Psychiatry, University of Edinburgh 753
- <sup>24</sup> Department of Clinical Sciences, Medical Faculty, Umeå University SE-901 87 754
- 755 Umeå

- Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska
   Institutet, Stockholm, SE
- 758 <sup>26</sup> Department of Psychiatric Research, Diakonhjemmet Hospital, Oslo, NO
- 759 27 NORMENT Centre, Division of Mental Health and Addiction, Institute of Clinical
- 760 Medicine and Diakonhjemmet Hospital, University of Oslo, Oslo, NO
- 761 <sup>28</sup> Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway
- 762 PORMENT Centre, Inst of Clinical Medicine, University of Oslo, Oslo, Norway
- 763 <sup>30</sup> Department of Psychiatry and Psychotherapy, University Medical Center 764 Göttingen, Germany
- 765 31 Division of Mental Health and Addiction, Oslo University Hosptial, Oslo, Norway
- Total Pharmacology, University Hospital Agency of Cagliari, Cagliari,
   Italy
- <sup>33</sup> Geneva University Hospitals, Department of Psychiatry
- 769 <sup>34</sup> University of Geneva, Faculty of medicine
- 770 <sup>35</sup> Department of Psychiatry, Psychosomatic Medicine and Psychotherapy,
- 771 University Hospital Frankfurt, Frankfurt am Main, Germany
- 772 <sup>36</sup> Universite de Paris, Paris, France
- 773 <sup>37</sup> INSERM UMRS 1144, Paris, France
- <sup>38</sup> APHP, DMU Neurosciences, GHU Lariboisière Fernand Widal, Departement de
- 775 Psychiatrie, Paris, France
- 776 <sup>39</sup> Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, 777 Catalonia, Spain
- 778 Department of Psychiatry and Psychotherapeutic Medicine, Medical University Graz, Graz, Austria
- 780 <sup>41</sup> Psychiatry, University of Pennsylvania, Philadelphia, PA, US
- 781 <sup>42</sup> Psychiatry, UMC Utrecht Brain Center, Utrecht, NL
- 782 <sup>43</sup> Department of Psychiatry, Stony Brook University, Stony Brook, NY, USA
- 783 <sup>44</sup> Psychiatry, University of California San Francisco, San Francisco, CA, US
- 784 <sup>45</sup> Department of Psychiatry, McGill University, Montreal, Canada
- 785 <sup>46</sup> Department of Biomedicine, University of Basel, Basel, Switzerland
- 786 <sup>47</sup> Institute of Human Genetics, University of Bonn, School of Medicine & University Hospital Bonn, Bonn, Germany
- 788 <sup>48</sup> Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, 789 Switzerland
- 790 <sup>49</sup> Institute of Neuroscience and Medicine (INM-1), Research Centre Julich, Julich, 791 Germany
- 792 <sup>50</sup> Discipline of Psychiatry, University of Adelaide, Australia
- 793 <sup>51</sup> Bazil Hetzel Institute, Woodville, South Australia, Australia
- 794 <sup>52</sup> Department of Psychiatry & Trinity Translational Medicine Institute, Trinity College 795 Dublin, Ireland
- 796 <sup>53</sup> University of Iowa Hospitals and Clinics, Iowa City, IA, US
- 797 <sup>54</sup> Medical Research Council Centre for Neuropsychiatric Genetics and Genomics,
- 798 Division of Psychological Medicine and Clinical Neurosciences
- 799 55 Translational Genomics, USC, Los Angeles, CA, US
- 800 <sup>56</sup> Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, US
- 801 <sup>57</sup> Department of Psychiatric Genetics, Poznan University of Medical Sciences, 802 Poznan, Poland
- 803 <sup>58</sup> Department of Child and Adolescent Psychiatry, Psychosomatics and
- 804 Psychotherapy, University Hospital Essen, University of Duisburg-Essen, Duisburg,
- 805 Germany

- <sup>59</sup> Department of Psychiatry and Behavioral Sciences, Johns Hopkins University 806
- 60 Department of Medical Genetics, Oslo University Hospital Ullevål, Oslo, NO 807
- <sup>61</sup> NORMENT, Department of Clinical Science, University of Bergen, Bergen, NO 808
- 62 Department of Biochemistry and Molecular Biology, Indiana University School of 809
- Medicine, Indianapolis, IN, USA 810
- NORMENT, Division of Mental Health and Addiction, Oslo University Hospital, 811
- 812 Oslo, Norway
- <sup>64</sup> Centre for Human Genetics, University of Marburg, Marburg, Germany 813
- <sup>65</sup> Neuroscience Research Australia 814
- <sup>66</sup> School of Medical Sciences, University of New South Wales 815
- Department of Psychiatry and Psychotherapy, University Medical Center 816
- 817 Göttingen, Germany
- <sup>68</sup> Nova Scotia Health Authority, Halifax, Canada 818
- <sup>69</sup> Department of Psychiatry and Behavioral Neuroscience, University of Chicago, 819
- 820 Chicago, IL, US
- <sup>70</sup> Department of Human Genetics, University of Chicago, Chicago, IL, US 821
- <sup>71</sup> Psychological Medicine, University of Worcester, UK 822
- 72 Mood Disorders Centre of Ottawa, Ottawa, ON, Canada 823
- <sup>73</sup> Dept of Psychiatry, University of Toronto, Toronto, ON, M5T 1R8, Canada 824
- <sup>74</sup> Mental Health Department, University Regional Hospital, Biomedicine Institute 825
- 826
- (IBIMA), Málaga, Spain
  <sup>75</sup> Universite Paris Est Creteil, Creteil, France 827
- <sup>76</sup> INSERM U 955, Neuropsychiatrie Translationnelle, Creteil, France 828
- 77 Department of Psychiatry and Neurochemistry, Institute of Neuroscience and 829
- Physiology, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg. 830
- 831
- Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, 832
- 833 NY, US
- <sup>79</sup> Department of Psychiatry, University of California San Diego, La Jolla, CA USA 834
- 835 The Campbell Family Mental Health Research Institute, Centre for Addiction and
- 836 Mental Health, Toronto, ON, M5T 1R8, Canada
- <sup>81</sup> Institute of Medical Science, University of Toronto, Toronto, ON, M5S 1A8, 837
- 838 Canada
- Department of Psychiatry, Psychotherapy and Psychosomatics, University 839
- 840 Hospital Wurzburg, Wurzburg, Germany
- <sup>83</sup> Cell Biology, SUNY Downstate Medical Center College of Medicine, Brooklyn, NY, 841
- 842 US
- Institute for Genomic Health, SUNY Downstate Medical Center College of 843
- 844 Medicine, Brooklyn, NY, US
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 845
- 846 Stockholm, Sweden
- Department of Psychiatry and Behavioral Sciences. Howard University Hospital. 847
- 848 Washington, DC, US
- <sup>87</sup> Neuroscience, Janssen Research & Development, LLC, Titusville, NJ 08560, USA 849
- <sup>88</sup> Departmeent of Psychiatry, University of Campania "Luigi Vanvitelli", Naples, Italy 850
- 89 Department of Genetics & Genomics, Icahn School of Medicine at Mount Sinai, 851
- <sup>90</sup> Unit of Psychiatry, Department of Public Health, Clinical & Molecular Medicine, 852
- 853 University of Cagliari, Cagliari, Italy
- <sup>91</sup> Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada 854
- <sup>92</sup> Research Institute, Lindner Center of HOPE, Mason, OH, US 855

- 856 <sup>93</sup> Department of Psychiatry, University of Michigan, Ann Arbor, MI, US
- 857 <sup>94</sup> Psychiatric Clinic, Alexander University Hospital, Sofia, Bulgaria
- 858 <sup>95</sup> School of Psychiatry, University of New South Wales
- 859 96 Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana",
- 860 University of Salerno, Baronissi, Salerno, Italy
- National Institute of Mental Health, Klecany, Czech Republic
- 862 <sup>98</sup> Psychiatry, Indiana University School of Medicine, Indianapolis, IN, US
- 863 <sup>99</sup> Department of Psychiatry, Dalhousie University, Halifax, Canada
- 864 <sup>100</sup> Dalhousie University
- 865 <sup>101</sup> Centre for Addiction and Mental Health, Toronto, Canada
- 866 <sup>102</sup> University of Toronto
- 867 103 Department of Biomedical Science, Section of Neuroscience & Clinical
- 868 Pharmacology, University of Cagliari, Cagliari, Italy
- 869 Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta, 870 GA
- 871 105 Montreal Neurological Institute, Montreal, Canada
- 872 106 Department of Neurology, McGill University, Montreal, Canada
- 873 Department of Psychiatry, Rush Medical College
- 874 Northern Adelaide Mental Health Service, SA Health, Salisbury, South Australia,
- 875 Australia

- 876 Psychiatry and the Behavioral Sciences, University of Southern California, Los Angeles, CA, US
- 878 Department of Psychiatry, University of Perugia, Perugia, Italy
- 879 111 Douglas Institute, McGill University, Montreal, Canada
- Dalla Lana School of Public Health, Biostatistics Division, University of Toronto,
   Toronto, ON, M5G 2M9, Canada
- Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, M5S
   1A8, Canada
- 884 <sup>114</sup> Harvard T.H. Chan School of Public Health, 677 Huntington Ave, Boston, MA 02115, United States
- 886 115 Psychiatric and Neurodevelopmental Genetics Unit, Department of Psychiatry and Center for Genomic Medicine, Massachusetts General Hospital USA
- 888 116 Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, USA
- 890 117 Department of Health Sciences Research, Mayo Clinic, Rochester, MN, US
- 891 Human Genetics Branch, Intramural Research Program, National Institute of Mental Health, Bethesda, MD, US
- 893 <sup>119</sup> Institute of Psychiatry, Psychology and Neuroscience, Kings College London, United Kingdom
- 895 Human Genetics, University of California Los Angeles, Los Angeles, CA, US
- Begin in the second of Medicine, Technical University of Munich, Munich, Germany
   Begin in the second of Medicine, Technical University of Munich, Munich, Germany
- 898 122 Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA
- 900 123 Department of Psychiatry and Behavioral Sciences, SUNY Upstate Medical University, Syracuse, NY, USA
- 902 124 Psychiatry, Erasmus University Medical Center, Rotterdam, The Netherlands

## 11. Tables and Figures

909

910

## Table 1. Sample characteristics of datasets used in genetic analyses

GWAS stage	Dataset	N	Continent	Diagnosis, % BD-I	Sex, % male	AAO, median (MAD <sup>+</sup> , range)	Definition of AAO	PAO*, N (%)	
Discovery	wtccc	1452	Europe	89.53%	36.85%	24 (8.9, 9-63)	Impairment / help-seeking		
	tgco2	865	North America	100%	33.64%	17 (5.93, 8-46)	Diagnostic interview	PAO-M: 316 (38.92%); PAO-D: 496 (61.08%)	
	gain	797	North America	100%	48.06%	18 (5.93, 8-45)	Diagnostic interview	PAO-M: 135 (18.57%); PAO-D: 440 (60.52%)	
	stp1	718	North America	100%	44.01%	16 (5.93, 8-41)	Diagnostic interview	PAO-M: 137 (19.08%); PAO-D: 420 (58.5%)	
	gsk1	715	North America	89.51%	36.36%	19 (7.51, 8-52)	Diagnostic interview	PAO-M: 102 (14.61%); PAO-D: 395 (56.59%)	
	usc2	681	North America	96.18%	47.58%	18 (7.41, 8-48)	Impairment / help-seeking		
	bonn	638	Europe	99.84%	47.34%	25 (8.9, 9-64)	Impairment / help-seeking		
	ucl2	604	Europe	100%	44.37%	30 (11.86, 9-60)	Pharmacotherapy	PAO-M: 47 (9.96%); PAO-D: 209 (44.28%)	
	bmg3	455	Europe	57.14%	40.66%	24 (10.38, 10-62)	Impairment / help-seeking	PAO-M: 43 (16.35%); PAO-D: 159 (60.46%)	
	m&m's	449	Europe	74.83%	52.12%	23 (10.38, 8-65)	Mixed	PAO-M: 73 (17.14%); PAO-D: 238 (55.87%)	
	uclo	439	Europe	100%	39.86%	22 (7.41, 8-51)	Impairment / help-seeking	PAO-M: 54 (14.25%); PAO-D: 197 (51.98%)	
	fran	411	Europe	77.62%	41.36%	22 (7.41, 10-58)	Diagnostic interview		
	euoR	410	Europe	75.85%	44.15%	22 (9.64, 11-59)	Mixed		
	hal2	355	North America	71.55%	42.54%	23 (8.9, 8-56)	Diagnostic interview	PAO-M: 102 (29.65%); PAO-D: 213 (61.92%)	
	ume4	354	Europe	69.21%	37.85%	20 (8.9, 8-63)	Diagnostic interview	PAO-M: 54 (14.25%); PAO-D: 197 (51.98%)	
	swa2	344	Europe	81.10%	41.86%	23 (10.38, 10-70)	Impairment / help-seeking		
	bmpo	319	Europe	78.06%	39.18%	28 (11.86, 10-63)	Impairment / help-seeking	PAO-M: 41 (16.33%); PAO-D: 150 (59.76%)	

	bmrom	126	Europe	100%	42.86%	24 (8.9, 12-56)	Diagnostic criteria	
	colo	176	South America	90.34%	31.82%	20 (11.86, 8-52)	Diagnostic interview	
	jst5	186	North America	100%	53.23%	16 (7.41, 8-51)	Unknown	
	dutch	468	Europe	100%	42.31%	28 (10.38, 11-63)	Pharmacotherapy	
Replication	ukwa1	1156	Europe	75.17%	38.15%	23 (8.9, 8-74)	Impairment / help-seeking	, ,
	Summary	12977		88.27%	41.57%	21 (8.9, 8-70)		PAO-M: 1435 (21.19%); PAO-D: 3885 (57.36%)
	dub1	51	Europe	100%	54.9%	21 (5.93, 12-45)	Diagnostic interview	
	euo2	58	Europe	65.52%	56.9%	26 (8.9, 18-57)	Diagnostic interview	
	auom	85	Australia	88.24%	45.88%	25 (10.38, 8-64)	Diagnostic interview	
	h66x	92	Europe	82.61%	36.96%	30 (10.38, 9-55)	Mixed	
	top8	111	Europe	55.86%	37.84%	18 (7.41, 8-49)	Diagnostic interview	
	bmg2	152	Europe	59.87%	35.53%	27 (10.38, 13-63)	Impairment / help-seeking	- (
	naom	159	North America	84.91%	44.65%	18 (7.41, 8-66)	Mixed	PAO-M: 30 (28.85%); PAO-D: 51 (49.04%)
	mich	169	North America	100%	31.36%	18 (5.93, 8-45)	Diagnostic interview	PAO-M: 42 (24.85%); PAO-D: 84 (49.7%)
	ageu	178	Europe	90.45%	39.33%	21 (7.41, 8-51)	Impairment / help-seeking	,
	euol	191	Europe	74.87%	31.41%	24 (8.9, 13-67)	Diagnostic interview	PAO-M: 48 (27.43%); PAO-D: 98 (56%)
	butr	204	Europe	100%	40.2%	22 (5.19, 13-44)	Impairment / help-seeking	
	rom3	226	Europe	100%	41.15%	25 (10.38, 12-59)	Diagnostic interview	PAO-M: 91 (40.27%); PAO-D: 134 (59.29%)
	edi1	244	Europe	99.18%	42.62%	20 (5.93, 13-50)	Diagnostic interview	. ,
	bmau	245	Australia	79.18%	40.82%	19 (7.41, 8-55)	Diagnostic interview	PAO-M: 46 (20.18%); PAO-D: 125 (54.82%)
	bmsp	248	Europe	94.76%	45.56%	22 (7.41, 9-57)	Impairment / help-seeking	PAO-M: 24 (10.04%); PAO-D: 93 (38.91%)
	may1	257	North America	100%	45.14%	20 (8.9, 8-62)	Diagnostic interview	PAO-M: 34 (13.23%); PAO-D: 142 (55.25%)
	top7	301	Europe	62.79%	41.53%	19 (7.41, 8-49)	Diagnostic interview	

	bdtrs	125	Europe	64%	45.6%	28 (13.34, 8-65)	Impairment / help-seeking	
	Summary	2237		84.40%	40.46%	24 (10.38, 8-74)		
All data		15214		86.26%	41.41%	22 (8.9, 8-74)		

- Abbreviations: GWAS, genome-wide association study; BD-I, bipolar disorder type I., AAO, age at onset; MAD, mean absolute deviation, PAO, polarity at onset;
- <sup>†</sup>We calculated the mean absolute deviation using 1.4826 as constant.
- \*We defined three categories of polarity at onset: PAO-M, mania/hypomania before depression; PAO-D, depression before
- mania/hypomania; and PAO-X, mixed. PAO was not available for all patients. The table presents the PAO-M and PAO-D subgroups
- 916 and their percentage within the individual cohorts.

## Table 2. The association of age and polarity at onset with disease characteristics in two European BD cohorts

Disease characteristic				AAO		PAO					
	N	Odds ratio	95% CI	Unadjusted <i>P</i> value	Adjusted P value*	N	Odds ratio	95% CI	Unadjusted P value	Adjusted P value	
Delusions	1612	0.71	0.64-0.79	1.61×10 <sup>-9</sup>	1.45×10 <sup>-8</sup>	1298	0.62	0.49-0.79	1.04×10 <sup>-4</sup>	6.24×10 <sup>-4</sup>	
Hallucinations	1594	0.83	0.74-0.92	3.5×10 <sup>-4</sup>	1.40×10 <sup>-3</sup>	1290	0.93	0.74-1.17	5.22×10 <sup>-1</sup>	1.00×10 <sup>0</sup>	
Current smoking	1594	0.98	0.89-1.09	7.50×10 <sup>-1</sup>	7.50×10 <sup>-1</sup>	1282	1.12	0.89-1.41	3.39×10 <sup>-1</sup>	1.00×100	
Suicidal ideation	1518	0.79	0.71-0.88	2.31×10 <sup>-5</sup>	1.62×10 <sup>-4</sup>	1280	1.68	1.32-2.13	2.11×10 <sup>-5</sup>	1.48×10 <sup>-4</sup>	
Suicide attempt	1537	0.78	0.69-0.88	2.73×10 <sup>-5</sup>	1.64×10 <sup>-4</sup>	1262	1.58	1.24-2.02	2.67×10 <sup>-4</sup>	1.48×10 <sup>-4</sup> 1.34×10 <sup>-3</sup> 1.00×10 <sup>0</sup>	
Educational attainment	1636	1.17	1.06-1.29	2.77×10 <sup>-3</sup>	8.31×10 <sup>-3</sup>	1319	1.06	0.85-1.33	5.93×10 <sup>-1</sup>	2	
Living together	1357	1.28	1.15-1.44	1.01×10 <sup>-5</sup>	8.08×10 <sup>-5</sup>	-	-	-	-	- (	
		Estimate**	SE	Unadjusted P value	Adjusted P value*		Estimate	SE	Unadjusted P value	Adjusted P value	
Number of manic episodes per illness year	1436	0.11	0.03	7.08×10 <sup>-5</sup>	3.54×10 <sup>-4</sup>	1156	-0.42	0.06	4.68×10 <sup>-13</sup>	3.74×10 <sup>-12</sup>	
Number of depressive episodes per illness year	1231	0.07	0.03	1.93×10 <sup>-2</sup>	3.86×10 <sup>-2</sup>	1051	0.12	0.06	4.63×10 <sup>-2</sup>	1.85×10 <sup>-1</sup>	

Abbreviations: AAO, age at onset; PAO, polarity at onset 918 919

N: total number of participants from the Dutch and German cohorts

The number of manic/depressive episodes was divided by (years of illness)+1. For secondary analyses of the number of episodes not corrected for the years of illness, see the Supplementary Material.

\* After Bonferroni-Holm correction. Significant adjusted P values are indicated in bold.

\*\* Unstandardized beta coefficient

917

920

921

922

- 926 **Figure 1:** Differences between phenotype definitions and continents across the 34
- 927 datasets used for genetic analyses
- 928 **A:** The various datasets used four different definitions for age at onset: diagnostic
- 929 interview, impairment/help-seeking, pharmacotherapy, and mixed.
- 930 **B:** The untransformed age at onset differed significantly, depending on the
- 931 phenotype definition used.
- 932 **C:** Estimation of the variance in different phenotype definitions explained by
- genotyped single-nucleotide variants ( $h^2_{SNV}$ ). For the cohort *wtccc*, we directly
- estimated  $h^2_{SNV}$  from genotype data in GCTA GREML; we estimated all other
- 935 heritabilities from GWAS summary statistics in LDSC. The plot shows  $h^2_{SNV}$
- 936 estimates and SEs.
- 937 Abbreviations: P, pharmacotherapy; I, impairment/help-seeking; M, mixed; D,
- 938 diagnostic interview; n.s., P>0.05; \*\*\* P<0.001, SNV, single-nucleotide variant; cont,
- 939 continent; AAO, age at onset; BD-I, BD type I; PAO, polarity at onset; PAO-M,
- 940 mania/hypomania before depression; PAO-D, depression before mania/hypomania;
- 941 PAO-X, mixed.

- 943 **Figure 2:** Results from the genome-wide association study (GWAS) and polygenic
- 944 score (PGS) analyses of bipolar disorder (BD) age at onset (AAO)
- 945 **A:** Manhattan plot of the discovery-stage GWAS
- 946 **B:** Locus-specific Manhattan plot of the top-associated variant. Mbp, mega base
- 947 pairs; cM, centi Morgan
- 948 **C-D:** Results from analyses of PGS. For detailed results, see Supplementary Table
- 949 S8. Significance levels: n.s., P>0.05; Nominal: P<0.05; Bonferroni, below the
- 950 Bonferroni-corrected significance threshold corrected for 96 tests (P<5.2×10<sup>-4</sup>).

Abbreviations: ADHD, attention deficit/hyperactivity disorder; ASD, autism spectrum disorder; MD, major depression; SZ, schizophrenia; EA, educational attainment. **C:** Associations of PGSs with the age at onset (AAO). For interpretability, the plot shows the untransformed AAO. Significance levels are based on the analyses of the AAO after rank-based inverse normal transformation (which was performed because the distribution of AAO was highly skewed and differed greatly across the study cohorts). D: Associations of the top vs bottom AAO quartiles with the top vs bottom PGS quartiles. A higher odds ratio (OR) indicates an association with higher AAO.

## 12. References

977

978

- 980 1. Merikangas KR, Jin R, He J-P, Kessler RC, Lee S, Sampson NA, et al.
  981 Prevalence and Correlates of Bipolar Spectrum Disorder in the World Mental
  982 Health Survey Initiative. Arch Gen Psychiatry [Internet]. 2011 Mar 7 [cited 2018
  983 Jul 18];68(3):241. Available from:
  984 http://archpsyc.jamanetwork.com/article.aspx?doi=10.1001/archgenpsychiatry.
  985 2011.12
- 986 2. Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, et al. 987 Global burden of disease attributable to mental and substance use disorders: 988 findings from the Global Burden of Disease Study 2010. Lancet [Internet]. 2013 989 Nov [cited 2018 Apr 11];382(9904):1575–86. Available from: 990 http://linkinghub.elsevier.com/retrieve/pii/S0140673613616116
- 991 3. Cloutier M, Greene M, Guerin A, Touya M, Wu E. The economic burden of 992 bipolar I disorder in the United States in 2015. J Affect Disord [Internet]. 2018 993 Jan 15 [cited 2018 Oct 23];226:45-51. Available from: 994 http://www.ncbi.nlm.nih.gov/pubmed/28961441
- Berk M, Dodd S, Callaly P, Berk L, Fitzgerald P, de Castella AR, et al. History of illness prior to a diagnosis of bipolar disorder or schizoaffective disorder. J Affect Disord [Internet]. 2007 Nov [cited 2020 Aug 29];103(1–3):181–6. Available from: https://pubmed.ncbi.nlm.nih.gov/17324469/
- Dagani J, Signorini G, Nielssen O, Bani M, Pastore A, Girolamo G de, et al. Meta-analysis of the Interval between the Onset and Management of Bipolar Disorder. Can J Psychiatry [Internet]. 2017 Apr 26 [cited 2019 May 17];62(4):247–58. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27462036
- Cleynen I, Boucher G, Jostins L, Schumm LP, Zeissig S, Ahmad T, et al. Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: A genetic association study. Lancet [Internet]. 2016 [cited 2020 Apr 19];387(10014):156–67. Available from: https://pubmed-ncbi-nlm-nih-gov.treadwell.idm.oclc.org/26490195/
- 7. Bergen SE, O'Dushlaine CT, Lee PH, Fanous AH, Ruderfer DM, Ripke S, et al. Genetic modifiers and subtypes in schizophrenia: Investigations of age at onset, severity, sex and family history. Schizophr Res [Internet]. 2014;154(1–3):48–53. Available from: http://dx.doi.org/10.1016/j.schres.2014.01.030
- 8. óNaj AC, Jun G, Reitz C, Kunkle BW, Perry W, Park YS, et al. Effects of multiple genetic loci on age at onset in late-onset Alzheimer disease: A genome-wide association study. JAMA Neurol. 2014 Nov 1;71(11):1394–404.
- 1016 9. Rhebergen D, Lamers F, Spijker J, De Graaf R, Beekman ATF, Penninx 1017 BWJH. Course trajectories of unipolar depressive disorders identified by latent class growth analysis. Psychol Med. 2012;42(7):1383–96.
- 1019 10. Howes OD, Lim S, Theologos G, Yung AR, Goodwin GM, McGuire P. A 1020 comprehensive review and model of putative prodromal features of bipolar 1021 affective disorder [Internet]. Vol. 41, Psychological Medicine. Psychol Med; 1022 2011 [cited 2020 Jul 1567-77. Available 261. 1023 https://pubmed.ncbi.nlm.nih.gov/20836910/
- 1024 11. Wijnands JMA, Kingwell E, Zhu F, Zhao Y, Högg T, Stadnyk K, et al. Health-1025 care use before a first demyelinating event suggestive of a multiple sclerosis

- prodrome: a matched cohort study. Lancet Neurol [Internet]. 2017 Jun 1 [cited 2020 Jul 26];16(6):445–51. Available from: https://pubmed.ncbi.nlm.nih.gov/28434855/
- 1029 12. Smoller JW, Finn CT. Family, twin, and adoption studies of bipolar disorder.
  1030 Am J Med Genet Part C Semin Med Genet [Internet]. 2003 Nov 15 [cited 2020 Jun 8];123C(1):48–58. Available from:
  1032 http://doi.wiley.com/10.1002/ajmq.c.20013
- 1033 13. Rice J, Reich T, Andreasen NC, Endicott J, Van Eerdewegh M, Fishman R, et al. The Familial Transmission of Bipolar Illness. Arch Gen Psychiatry. 1987;44(5):441–7.
- Hafeman DM, Merranko J, Goldstein TR, Axelson D, Goldstein BI, Monk K, et 1036 14. 1037 al. Assessment of a Person-Level Risk Calculator to Predict New-Onset Bipolar Spectrum Disorder in Youth at Familial Risk. JAMA Psychiatry [Internet]. 2017 1038 1039 [cited Aug 2018 Oct 18];74(8):841. Available from: 1040 http://archpsyc.jamanetwork.com/article.aspx?doi=10.1001/jamapsychiatry.201 1041 7.1763
- 1042 15. Belmonte Mahon P, Pirooznia M, Goes FS, Seifuddin F, Steele J, Lee PH, et 1043 al. Genome-wide association analysis of age at onset and psychotic symptoms 1044 in bipolar disorder. Am J Med Genet B Neuropsychiatr Genet [Internet]. 2011 1045 29];156B(3):370-8. Apr [cited 2015 Sep Available from: 1046 http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3178836&tool=pmce 1047 ntrez&rendertype=abstract
- 1048 16. Ruderfer DM, Ripke S, McQuillin A, Boocock J, Stahl EA, Pavlides JMW, et al. 1049 Genomic Dissection of Bipolar Disorder and Schizophrenia, Including 28 Subphenotypes. Cell [Internet]. 2018 Jun;173(7):1705-1715.e16. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0092867418306585
- 17. Jamain S, Cichon S, Etain B, Muhleisen TW, Georgi A, Zidane N, et al. Common and rare variant analysis in early-onset bipolar disorder vulnerability. PLoS One [Internet]. 2014 Jan [cited 2016 Aug 1];9(8):e104326. Available from:
- http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4128749&tool=pmce ntrez&rendertype=abstract
- 1058 18. Stahl EA, Breen G, Forstner AJ, McQuillin A, Ripke S, Trubetskoy V, et al. Genome-wide association study identifies 30 loci associated with bipolar disorder. Nat Genet [Internet]. 2019 [cited 2020 Feb 23];51(5):793–803. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31043756
- Coleman JRI, Gaspar HA, Bryois J, Byrne EM, Forstner AJ, Holmans PA, et al. 1062 19. The Genetics of the Mood Disorder Spectrum: Genome-wide Association 1063 1064 Analyses of More Than 185,000 Cases and 439,000 Controls. Biol Psychiatry 1065 [Internet]. 2020 [cited 31: Available 2020 May 1066 https://pubmed.ncbi.nlm.nih.gov/31926635/
- 1067 20. Kalman JL, Papiol S, Forstner AJ, Heilbronner U, Degenhardt F, Strohmaier J,
   1068 et al. Investigating polygenic burden in age at disease onset in bipolar disorder:
   1069 Findings from an international multicentric study. Bipolar Disord [Internet]. 2019
   1070 Jun 28;21(1):68–75. Available from: http://doi.wiley.com/10.1111/bdi.12659
- 1071 21. Aas M, Bellivier F, Bettella F, Henry C, Gard S, Kahn JP, et al. Childhood maltreatment and polygenic risk in bipolar disorders. Bipolar Disord [Internet]. 2020 Mar 1 [cited 2020 Nov 16];22(2):174–81. Available from: https://pubmed.ncbi.nlm.nih.gov/31628696/
- 1075 22. Kassem L, Lopez V, Hedeker D, Steele J, Zandi P, Bipolar Disorder Consortium NGI, et al. Familiality of Polarity at Illness Onset in Bipolar Affective

- 1077 Disorder. 2006 Am J Psychiatry [Internet]. Oct [cited 2018 Nov 1078 15]:163(10):1754–9. Available from: 1079 http://www.ncbi.nlm.nih.gov/pubmed/17012686
- 1080 23. Ruderfer DM, Ripke S, McQuillin A, Boocock J, Stahl EA, Pavlides JMW, et al. 1081 Genomic Dissection of Bipolar Disorder and Schizophrenia, Including 28 Subphenotypes. Cell. 2018;173(7):1705-1715.e16.
- 24. Schulze TG, Alda M, Adli M, Akula N, Ardau R, Bui ET, et al. The International Consortium on Lithium Genetics (ConLiGen): an initiative by the NIMH and IGSLI to study the genetic basis of response to lithium treatment. Neuropsychobiology [Internet]. 2010 [cited 2017 Jul 1];62(1):72–8. Available from: http://www.karger.com/doi/10.1159/000314708
- van Bergen AH, Verkooijen S, Vreeker A, Abramovic L, Hillegers MH, Spijker AT, et al. The characteristics of psychotic features in bipolar disorder. Psychol Med [Internet]. 2019 Sep 10 [cited 2020 May 17];49(12):2036–48. Available from:
- https://www.cambridge.org/core/product/identifier/S0033291718002854/type/journal\_article
- 26. Budde M, Anderson-Schmidt H, Gade K, Reich-Erkelenz D, Adorjan K, Kalman JL, et al. A longitudinal approach to biological psychiatric research: The PsyCourse study. Am J Med Genet B Neuropsychiatr Genet [Internet]. 2019 [cited 2020 Feb 23];180(2):89–102. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30070057
- 1099 27. Kircher T, Wöhr M, Nenadic I, Schwarting R, Schratt G, Alferink J, et al.
  1100 Neurobiology of the major psychoses: a translational perspective on brain
  1101 structure and function—the FOR2107 consortium. Eur Arch Psychiatry Clin
  1102 Neurosci [Internet]. 2019 [cited 2020 May 3];269(8):949–62. Available from:
  1103 https://pubmed.ncbi.nlm.nih.gov/30267149/
- Perlis RH, Miyahara S, Marangell LB, Wisniewski SR, Ostacher M, DelBello MP, et al. Long-term implications of early onset in bipolar disorder: data from the first 1000 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry [Internet]. 2004 May 1 [cited 2020 Feb 22];55(9):875–81. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15110730
- Lam M, Awasthi S, Watson HJ, Goldstein J, Panagiotaropoulou G, Trubetskoy V, et al. RICOPILI: Rapid Imputation for COnsortias PlpeLIne. Bioinformatics [Internet]. 2020 [cited 2020 May 3];36(3):930–3. Available from: https://pubmed.ncbi.nlm.nih.gov/31393554/
- Howie BN, Donnelly P, Marchini J. A Flexible and Accurate Genotype Imputation Method for the Next Generation of Genome-Wide Association Studies. Schork NJ, editor. PLoS Genet [Internet]. 2009 Jun 19 [cited 2020 May 19];5(6):e1000529. Available from: https://dx.plos.org/10.1371/journal.pgen.1000529
- 1119 31. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, et al.
  1120 PLINK: a tool set for whole-genome association and population-based linkage
  1121 analyses. Am J Hum Genet [Internet]. 2007 Sep [cited 2017 Aug 5];81(3):559–
  1122 75. Available from:
- http://linkinghub.elsevier.com/retrieve/pii/S0002929707613524
- 1124 32. METAL: fast and efficient meta-analysis of genomewide association scans [Internet]. [cited 2020 Jun 14]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2922887/
- 1127 33. Demontis D, Walters RK, Martin J, Mattheisen M, Als TD, Agerbo E, et al.

- Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder. Nat Genet. 2019;51(1):63–75.
- 1130 34. Grove J, Ripke S, Als TD, Mattheisen M, Walters RK, Won H, et al. Identification of common genetic risk variants for autism spectrum disorder. Nat Genet [Internet]. 2019 [cited 2020 Feb 26];51(3):431–44. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30804558
- 1134 35. Lee JJ, Wedow R, Okbay A, Kong E, Maghzian O, Zacher M, et al. Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals. Nat Genet. 2018 Aug 1;50(8):1112–21.
- Howard DM, Adams MJ, Clarke TK, Hafferty JD, Gibson J, Shirali M, et al. Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. Nat Neurosci. 2019 Mar 1;22(3):343–52.
- 1142 37. Pardiñas AF, Holmans P, Pocklington AJ, Escott-Price V, Ripke S, Carrera N, et al. Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. Nat Genet. 2018 Mar 1;50(3):381–9.
- 1146 38. Ge T, Chen CY, Ni Y, Feng YCA, Smoller JW. Polygenic prediction via 1147 Bayesian regression and continuous shrinkage priors. Nat Commun [Internet]. 2020 1148 2019 [cited May 19];10(1). Available https://pubmed.ncbi.nlm.nih.gov/30992449/?from\_single\_result=tian+ge+prs+c 1149 1150 s&expanded search query=tian+qe+prs+cs
- 1151 39. Yang J, Lee SH, Goddard ME, Visscher PM. GCTA: A tool for genome-wide complex trait analysis. Am J Hum Genet. 2011 Jan 7;88(1):76–82.
- 1153 40. Yang J, Benyamin B, McEvoy BP, Gordon S, Henders AK, Nyholt DR, et al.
  1154 Common SNPs explain a large proportion of the heritability for human height.
  1155 Nat Genet. 2010 Jul;42(7):565–9.
- Hulik-Sullivan B, Loh PR, Finucane HK, Ripke S, Yang J, Patterson N, et al. LD score regression distinguishes confounding from polygenicity in genome-wide association studies. Nat Genet. 2015 Feb 25;47(3):291–5.
- Heimbuch RC, Matthysse S, Kidd KK. Estimating age-of-onset distribution for disorders with variable onset. Am J Hum Genet [Internet]. 1980 [cited 2020 Sep 10];32(4):564–74. Available from: /pmc/articles/PMC1686126/?report=abstract
- Larsson S, Lorentzen S, Mork E, Barrett EA, Steen NE, Lagerberg TV, et al. Age at onset of bipolar disorder in a Norwegian catchment area sample. J Affect Disord. 2010 Jul 1:124(1–2):174–7.
- Host RM, Luckenbaugh DA, Leverich GS, Altshuler LL, Frye MA, Suppes T, et al. Incidence of childhood-onset bipolar illness in the USA and Europe. Br J Psychiatry [Internet]. 2008 Feb [cited 2020 Sep 14];192(2):150–1. Available from: https://www.cambridge.org/core.
- 1169 45. Cai N, Revez JA, Adams MJ, Andlauer TFM, Breen G, Byrne EM, et al.
  1170 Minimal phenotyping yields genome-wide association signals of low specificity
  1171 for major depression. Nat Genet. 2020 Apr 1;52(4):437–47.
- 46. Andlauer TFM, Buck D, Antony G, Bayas A, Bechmann L, Berthele A, et al. Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation. Sci Adv [Internet]. 2016 Jun 17 [cited 2017 Aug 22];2(6):e1501678. Available from: http://advances.sciencemag.org/cgi/doi/10.1126/sciadv.1501678
- 1176 47. Vreeker A, Boks MPM, Abramovic L, Verkooijen S, Van Bergen AH, Hillegers MHJ, et al. High educational performance is a distinctive feature of bipolar disorder: A study on cognition in bipolar disorder, schizophrenia patients,

- relatives and controls. Psychol Med [Internet]. 2016 Mar 1 [cited 2020 Nov 16];46(4):807–18. Available from: https://pubmed.ncbi.nlm.nih.gov/26621616/
- 48. MacCabe JH, Lambe MP, Cnattingius S, Sham PC, David AS, Reichenberg A,
   et al. Excellent school performance at age 16 and risk of adult bipolar disorder:
   National cohort study. Br J Psychiatry [Internet]. 2010 Feb [cited 2020 Nov
   16];196(2):109–15. Available from: https://pubmed.ncbi.nlm.nih.gov/20118454/
- 1185 Mullins N, Forstner AJ, O'Connell KS, Coombes B, Coleman JRI, Qiao 49. Z, et al. Genome-wide association study of over 40,000 bipolar disorder cases 1186 1187 novel biological insights. medRxiv [Internet]. provides 2020 1188 1:2020.09.17.20187054. Available from: 1189 http://medrxiv.org/content/early/2020/09/18/2020.09.17.20187054.abstract
- Robinson MR, Wray NR, Visscher PM. Explaining additional genetic variation in complex traits. Trends Genet [Internet]. 2014 [cited 2020 May 16];30(4):124. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4639398/
- 1193 51. Montlahuc C, Curis E, Jonas SF, Bellivier F, Chevret S. Age-at-onset subsets 1194 of bipolar I disorders: A critical insight into admixture analyses. Int J Methods 1195 Psychiatr Res [Internet]. 2016 Oct 21 [cited 2017 Jul 27]; Available from: 1196 http://www.ncbi.nlm.nih.gov/pubmed/27766706
- 1197 52. Cooper JE. Psychiatric diagnosis in New York and London; a comparative 1198 study of mental hospital admissions [Internet]. Maudsley monographs, no. 20. 1199 1972 [cited 2020 Jun 261. χi, 152. Available from: 1200 https://psycnet.apa.org/record/1973-23416-000
- 1201 53. Bellivier F, Etain B, Malafosse A, Henry C, Kahn JP, Elgrabli-Wajsbrot O, et al.
  1202 Age at onset in bipolar I affective disorder in the USA and Europe. World J Biol
  1203 Psychiatry [Internet]. 2014 [cited 2020 Jun 27];15(5):369–76. Available from:
  1204 https://pubmed.ncbi.nlm.nih.gov/22188366/
- 1205 54. Birmaher B, Axelson D, Goldstein B, Strober M, Gill MK, Hunt J, et al. Four-1206 year longitudinal course of children and adolescents with bipolar spectrum 1207 disorders: the Course and Outcome of Bipolar Youth (COBY) study. Am J 1208 Psychiatry [Internet]. 2009 Jul [cited 2018 Oct 21];166(7):795–804. Available 1209 from: http://www.ncbi.nlm.nih.gov/pubmed/19448190
- 1210 55. Daban C, Colom F, Sanchez-Moreno J, García-Amador M, Vieta E. Clinical correlates of first-episode polarity in bipolar disorder. Compr Psychiatry [Internet]. 2006 Nov [cited 2020 Jul 26];47(6):433–7. Available from: https://pubmed.ncbi.nlm.nih.gov/17067865/
- Etain B, Lajnef M, Bellivier F, Mathieu F, Raust A, Cochet B, et al. Clinical expression of bipolar disorder type I as a function of age and polarity at onset: Convergent findings in samples from France and the United States. J Clin Psychiatry [Internet]. 2012 [cited 2020 Jul 26];73(4). Available from: https://pubmed.ncbi.nlm.nih.gov/22579163/
- 1219 57. Cremaschi L, Dell'Osso B, Vismara M, Dobrea C, Buoli M, Ketter TA, et al.
  1220 Onset polarity in bipolar disorder: A strong association between first depressive
  1221 episode and suicide attempts. J Affect Disord [Internet]. 2017 Feb 1 [cited 2020
  1222 Jul 26];209:182–7. Available from: https://pubmed.ncbi.nlm.nih.gov/27936451/
- 58. Smoller JW. The use of electronic health records for psychiatric phenotyping and genomics. Am J Med Genet Part B Neuropsychiatr Genet. 2018;177(7):601–12.
- Thang Y, Cai T, Yu S, Cho K, Hong C, Sun J, et al. High-throughput phenotyping with electronic medical record data using a common semi-supervised approach (PheCAP). Nat Protoc [Internet]. 2019;14(12):3426–44.
- 1229 Available from: http://dx.doi.org/10.1038/s41596-019-0227-6


1230 60. Sullivan PF, Agrawal A, Bulik CM, Andreassen OA, Børglum AD, Breen G, et 1231 al. Psychiatric genomics: An update and an Agenda. Am J Psychiatry. 1232 2018;175(1):15–27.

**Figure 1:** Differences between phenotype definitions and continents across the 34 datasets used for genetic analyses

**A:** The various datasets used four different definitions for age at onset: diagnostic interview, impairment/help-seeking, pharmacotherapy, and mixed.

**B:** The untransformed age at onset differed significantly, depending on the phenotype definition used. Abbreviations: P, pharmacotherapy; I, impairment/help-seeking; M, mixed; D, diagnostic interview; *n.s.*, *P*>0.05; \*\*\* *P*<0.001.

**C:** Estimation of the variance in different phenotype definitions explained by genotyped single-nucleotide variants ( $h^2_{SNV}$ ). For the cohort *wtccc*, we directly estimated  $h^2_{SNV}$  from genotype data in GCTA GREML; we estimated all other heritabilities from GWAS summary statistics in LDSC. The plot shows  $h^2_{SNV}$  estimates and SEs. Abbreviations: SNV, single-nucleotide variant; cont, continent; AAO, age at onset; BD-I, BD type I; PAO, polarity at onset; PAO-M, mania/hypomania before depression; PAO-D, depression before mania/hypomania; PAO-X, mixed.



**Figure 2:** Results from the genome-wide association study (GWAS) and polygenic score (PGS) analyses of bipolar disorder (BD) age at onset (AAO)

A: Manhattan plot of the discovery-stage GWAS.

**B:** Locus-specific Manhattan plot of the top-associated variant. Mbp, mega base pairs; cM, centi Morgan.

**C-D:** Results from analyses of PGS. For detailed results, see Supplementary Table S8. Significance levels: n.s., *P*>0.05; Nominal, *P*<0.05; Bonferroni, below the Bonferroni-corrected significance threshold corrected for 96 tests (*P*<5.2×10<sup>-4</sup>). Abbreviations: ADHD, attention deficit/hyperactivity disorder; ASD, autism spectrum disorder; MD, major depression; SZ, schizophrenia; EA, educational attainment. **C:** For interpretability, the plot shows the untransformed AAO. Significance levels are based on the analyses of the AAO after rank-based inverse normal transformation (which was performed because the distribution of AAO was highly skewed and differed greatly across the study cohorts).

**D**: Associations of the top vs bottom AAO quartiles with the top vs bottom PGS quartiles. A higher odds ratio (OR) indicates an association with higher AAO.

